Zydus introduces biosimilar Aflibercept 2 mg Anyra for advancing ophthalmic care: Our Bureau, Mumbai Thursday, February 19, 2026, 15:45 Hrs [IST] Zydus Lifesciences Ltd., an innov ...

Boost your productivity with the best 5 2-in-1 convertible laptops from HP, Lenovo, and Dell. Ideal for students, ...

TCL C7K vs Amazon Fire TV Omni Mini-LED: which budget-friendly Mini LED TV should you buy?

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

AMD has a solid track record of substantial rallies. The stock has increased by over 50% within two months on several occasions, particularly in 2013 and 2021.

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

COLUMBUS, Ohio (WCMH) — Wednesday, 25 children with severe visual impairment were given high-tech vision aids and taught how to use them from the non-profit “Sight Savers America.” Some of the devices ...

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the treatment of wet age-related macular degeneration, according to a press ...

Ocular Therapeutix (OCUL) stock falls as the company posts late-stage trial data for Axpaxli, its experimental drug for Wet AMD. Read more here.

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...